SBIR Phase I: A Novel Low Cost Intradermal Delivery Platform For Nucleic Acid Vaccines — NSF Award to PIEZO THERAPEUTICS, INC. (GA
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a new portable low cost vaccine delivery platform for nucleic acid vaccines, commonly used to treat infectious diseases and cancer. Current vaccines are delivered using lipid nanoparticles (LNPs) which are gener
| Award title | SBIR Phase I: A Novel Low Cost Intradermal Delivery Platform For Nucleic Acid Vaccines |
|---|---|
| Award ID | 2437939 |
| Awardee | PIEZO THERAPEUTICS, INC. |
| City | CUMMING |
| State | GA |
| Amount obligated | $304,742 |
| Principal investigator | Gaurav Byagathvalli |
| Program | SBIR Phase I |
| Start date | 10/01/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a new portable low cost vaccine delivery platform for nucleic acid vaccines, commonly used to treat infectious diseases and cancer. Current vaccines are delivered using lipid nanoparticles (LNPs) which are generally considered complex and generally more costly to produce. Furthermore they can exhibit undesirable side effects. These challenges have caused a steady decline in actual adoptio |
| Source | NSF Awards |
$799/mo
Try NSFGrants →